Stock Splits
By The Online Investor Staff, updated Sat., Sep. 19, 5:06 AM
| This Slide: #7 of 25 |
Slide #7. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) — 1 for 10 Reverse Split
Announced:
9/2/2020
Stock Split:
1 for 10
Record Date:
9/2/2020
Pay Date:
9/3/2020
SNSS Optionable?:
Yes
Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development of targeted inhibitors for the treatment of hematologic and solid cancers. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology and conducting clinical trials. Co.'s primary program is vecabrutinib, a selective non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. 
SNSS Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the SNSS Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Hold (2.00 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
